Aprogen Biologics Statistics
Want to see KR:003060 full AI Analyst Report?
Aprogen Biologics (003060) Stock Statistics & Valuation Metrics
Total Valuation
Aprogen Biologics has a market cap or net worth of KRW 35.43B. The enterprise value is KRW 305.99B.
- Market Cap
- KRW 35.43B
- Enterprise Value
- KRW 305.99B
Share Statistics
Aprogen Biologics has 30,079,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 30,079,500
- Owned by Insiders
- ―
- Owned by Institutions
- 0.02%
Financial Efficiency
Aprogen Biologics’s return on equity (ROE) is -0.82 and return on invested capital (ROIC) is -23.13%.
- Return on Equity (ROE)
- -0.82
- Return on Assets (ROA)
- -0.29
- Return on Invested Capital (ROIC)
- -23.13%
- Return on Capital Employed (ROCE)
- -0.34
- Revenue Per Employee
- 194.23M
- Profits Per Employee
- -451.81M
- Employee Count
- 377
- Asset Turnover
- 0.12
- Inventory Turnover
- 1.97
Valuation Ratios
The current PE Ratio of Aprogen Biologics is -0.23. Aprogen Biologics’s PEG ratio is -0.00.
- PE Ratio
- -0.23
- PS Ratio
- 0.18
- PB Ratio
- 0.10
- Price to FCF
- -0.48
- Price to Operating Cash Flow
- -0.66
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Aprogen Biologics had revenue of 73.23B and earned -170.33B in profits. Earnings per share was -12923.54.
- Revenue
- 73.23B
- Gross Profit
- -28.42B
- Operating Income
- -122.89B
- Pretax Income
- -169.38B
- Net Income
- -170.33B
- EBITDA
- -103.70B
- Earnings Per Share (EPS)
- -12923.54
Cash Flow
In the last 12 months, operating cash flow was -32.32B and capital expenditures -3.83B, giving a free cash flow of -36.15B billion.
- Operating Cash Flow
- -32.32B
- Free Cash Flow
- -36.15B
- Free Cash Flow per Share
- -1958.40
Dividends & Yields
Aprogen Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -207.90%
- Earnings Yield
- -378.77%
Stock Price Statistics
- Beta
- 0.07
- 52-Week Price Change
- -86.35%
- 50-Day Moving Average
- 1473.90
- 200-Day Moving Average
- 2802.35
- Relative Strength Index (RSI)
- 23.72
- Average Volume (3m)
- 311.36K
Important Dates
Aprogen Biologics upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Aprogen Biologics as a current ratio of 0.67, with Debt / Equity ratio of 108.46%
- Current Ratio
- 0.67
- Quick Ratio
- 0.45
- Debt to Market Cap
- 2.02
- Net Debt to EBITDA
- -1.94
- Interest Coverage Ratio
- -11.49
Taxes
In the past 12 months, Aprogen Biologics has paid -1.08B in taxes.
- Income Tax
- -1.08B
- Effective Tax Rate
- 0.01
Enterprise Valuation
Aprogen Biologics EV to EBITDA ratio is -10.05, with an EV/FCF ratio of -6.71.
- EV to Sales
- 2.45
- EV to EBITDA
- -10.05
- EV to Free Cash Flow
- -6.71
- EV to Operating Cash Flow
- -7.28
Balance Sheet
Aprogen Biologics has KRW 22.70B in cash and marketable securities with KRW 210.84B in debt, giving a net cash position of -KRW 188.14B billion.
- Cash & Marketable Securities
- KRW 22.70B
- Total Debt
- KRW 210.84B
- Net Cash
- -KRW 188.14B
- Net Cash Per Share
- -KRW 6,254.74
- Tangible Book Value Per Share
- KRW 19.14K
Margins
Gross margin is -23.69%, with operating margin of -140.72%, and net profit margin of -83.47%.
- Gross Margin
- -23.69%
- Operating Margin
- -140.72%
- Pretax Margin
- -74.01%
- Net Profit Margin
- -83.47%
- EBITDA Margin
- -24.41%
- EBIT Margin
- -130.91%
Analyst Forecast
The average price target for Aprogen Biologics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 17.80%
- EPS Growth Forecast
- 64.55%
Scores
- Smart Score
- ―
- AI Score
- 40

